Proactive Investors - Run By Investors For Investors

AstraZeneca gets US regulatory green light for slow-release diabetes drug

Qternmet XR will be prescribed alongside diet and exercise advice to people to improve glycaemic control
green traffic light
America’s Food & Drug Administration gave the nod for the once-a-day treatment after the Anglo-Swedish drugs giant successfully carried out two phase III clinical trials

AstraZeneca PLC (LON:AZN) has received the US regulatory green light for a slow-release version of its type-2 diabetes treatment.

Qternmet XR will be prescribed alongside diet and exercise advice to people to improve glycaemic control.

America’s Food & Drug Administration gave the nod for the once-a-day treatment after the Anglo-Swedish drugs giant successfully carried out two phase III clinical trials.

View full AZN profile View Profile

AstraZeneca Timeline

Related Articles

scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
A stomach adenocarcinoma
February 13 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
A woman with severe depression
April 25 2019
The New York clinical-stage biopharmaceutical company has several drugs in the pipeline capable of generating hefty revenue

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use